Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Peter Clark, MA, MD, FRCP: A Payer Perspective

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Advertisement

Advertisement




Aug
24
Today In Oncology
Outreach to HCT Recipients, Primary Care Doctors May Reduce Skin Cancer Risk
FDA Seeks Public Input Relating to Regulatory Considerations for Generative AI–Enabled Medical Devices
Pilots and Flight Attendants Show Elevated Radiation-Related Cancer Mortality
INTerpath-001 Trial of mRNA-Based Individualized Neoantigen Therapy Meets Primary and Key Secondary Endpoints in Patients With High-Risk Resected Melanoma
Early Histotripsy Use for Liver Tumors Raises Questions About Patient Selection
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo